776 related articles for article (PubMed ID: 28342334)
1. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
4. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
7. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
13. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
Lu S; Azada MC; Ou SH
Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
[TBL] [Abstract][Full Text] [Related]
14. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
16. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
17. ROS1 [corrected].
Pal P; Khan Z
J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
[TBL] [Abstract][Full Text] [Related]
18. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
19. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
20. Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.
Sun TY; Niu X; Chakraborty A; Neal JW; Wakelee HA
J Thorac Oncol; 2019 Feb; 14(2):e21-e24. PubMed ID: 30217491
[No Abstract] [Full Text] [Related]
[Next] [New Search]